The sudden resignation of Peter Marks, M.D., Ph.D., from the FDA branch that regulates biological products for humans ...

The downgrade was driven by weaker-than-anticipated feedback from physicians regarding ELEVIDYS, suggesting that market reception for the treatment had fallen short. Notably, ELEVIDYS had been a ...

The downgrade was driven by weaker-than-anticipated feedback from physicians regarding ELEVIDYS, suggesting that market reception for the treatment had fallen short. Notably, ELEVIDYS had been a big ...

In the brain, molecular information is transmitted between cells through neural circuits. Synapses establish connections between the pathways that run from one area to another, allowing the most ...

The patient died from acute liver failure months after starting Elevidys, the only FDA-approved gene therapy for DMD. Its maker, Sarepta Therapeutics, hasn’t ruled out the possibility that the ...

The death of a patient treated with Sarepta's Duchenne muscular dystrophy (DMD) gene therapy Elevidys has played havoc with its share price – although analysts believe that its benefits still ...

Heavy ligands such as polyoxometalates are opening a new frontier in actinide chemistry. Studying materials that are both ...

Medtronic plc’s Evolut Low-Risk trial continued to show non-inferiority of transcatheter aortic valve replacement to surgical aortic valve replacement in terms of death or disabling stroke at five ...

Mizuho Securities analyst Uy Ear maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report) today and set a price target of $190.00. The company’s shares closed last Friday at $ ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on March 31, 2025 that were ...